Kenneth Fan
Ophthalmology · Bellaire, TXNPI 1780032839
Payments from drug & device makers
Across 241 payments — averaging $1106.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$103K
- Alnylam Pharmaceuticals Inc.$48K
- Novartis$30K
- Eyepoint US, Inc.$20K
- Janssen Research & Development, LLC$19K
- AbbVie$13K
- plus $34K from 20 others
What the payments were for
- Consulting fees$22,40354%
- Speaking & faculty fees$12,62431%
- Travel & lodging$990%
- Food & beverage$6,16315%
- Education$310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 13 | $103,045 |
| Alnylam Pharmaceuticals Inc. | 10 | $48,118 |
| Novartis | 4 | $30,030 |
| Eyepoint US, Inc. | 5 | $19,849 |
| Janssen Research & Development, LLC | 15 | $18,732 |
| AbbVie(2 entities) | 23 | $13,289 |
| Regeneron Healthcare Solutions, Inc. | 37 | $12,537 |
| Insmed, Inc. | 4 | $4,408 |
| Astellas Pharma US Inc | 27 | $3,494 |
| Boehringer Ingelheim International GmbH | 34 | $3,251 |
| Ocular Therapeutix, Inc. | 4 | $2,299 |
| Johnson & Johnson | 1 | $1,815 |
| Alimera Sciences, Inc. | 10 | $1,706 |
| Regeneron | 4 | $1,255 |
| Alcon | 10 | $784 |
| Harrow Eye, LLC | 4 | $457 |
| Apellis Pharmaceuticals, Inc. | 10 | $417 |
| Genentech USA, Inc. | 9 | $286 |
| Biogen | 9 | $185 |
| Sight Sciences, Inc. | 1 | $138 |
| ANI Pharmaceuticals, Inc. | 1 | $130 |
| Oyster Point Pharma, Inc. | 1 | $122 |
| Sun Pharmaceutical Industries Inc. | 1 | $100 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $86 |
| Dutch Ophthalmic, USA | 2 | $53 |
| Itamar Medical Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA HD$11,368
- OZURDEX$4,200
- YUTIQ$3,730
- Izervay$2,847
- EYP-1901$1,850
- EYLEA$1,500
- Iluvien$1,390
- IHEEZO$435
- Clareon$144
- OMNI(R) SURGICAL SYSTEM (US)$138
- Constellation$129
- TYRVAYA$122
- DUREZOL$120
- AcrySof IQ VIVITY IOL$112
How this compares
$266,602 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 134 | $6,558 |
| Bromfenac Sodium | 11 | $2,127 |
| MoxifloxacinMoxifloxacin Hcl | 52 | $993 |
| Atropine Sulfate | 30 | $888 |
| Ketorolac Tromethamine | 37 | $736 |
| Brimonidine Tartrate | 29 | $387 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 34 | $387 |
| Timolol Maleate | 37 | $247 |
| Dorzolamide Hcl | 19 | $219 |
| Cyclopentolate Hcl | 13 | $163 |
| Latanoprost | 11 | $66 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Bellaire
- Charles WykoffBellaire$73.4M
- Hasenin Al-KhersanBellaire$1.9M
- Effie RahmanBellaire$555K
- Otis WaltonBellaire$493K
- Kelly LarkinBellaire$486K
- David BrownHouston$51.7M
- Sunil PatelAbilene$11.1M
- Chirag JhaveriAustin$9.4M
- Robert WongAustin$6.6M
- Fuad MakkoukAustin$6.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.